945244-26-8 Usage
General Description
Diethyl 2-(2-bromo-4-nitrophenyl)-2-methylmalonate, also known as DEBM, is a chemical compound often used in various types of research and laboratory experiments. Diethyl 2-(2-bromo-4-nitrophenyl)-2-methylmalonate contains elements such as bromine, nitrogen, and oxygen in its structure. It belongs to the family of phenols and derivatives and is characterized by a benzene ring bearing a hydroxyl group. Being a relatively complex compound, DEBM requires careful handling, storage, and disposal to ensure its safe application. Numerous databases host detailed information about this compound's molecular structure, properties, safety guidelines, and potential applications in scientific and industrial settings.
Check Digit Verification of cas no
The CAS Registry Mumber 945244-26-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,5,2,4 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 945244-26:
(8*9)+(7*4)+(6*5)+(5*2)+(4*4)+(3*4)+(2*2)+(1*6)=178
178 % 10 = 8
So 945244-26-8 is a valid CAS Registry Number.
945244-26-8Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 1242, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
